OIPE JC106 JUN 01 2004 PATENT & TRADEMARK OFFICE

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 3840-005-27	SERIAL NO. 10/725,013
		APPLICANT Lakshman R. SEHGAL et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		FILING DATE December 2, 2003	GROUP ART UNIT ~~1623~~ 1635

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AA	Brian S. ZUCKERBRAUN et al., "Vascular Gene Therapy, A Reality of the 21st Century," Arch. Surg. 137:854-61 (2002).
	AB	Melina R. KIBBE et al., "Gene Therapy for Restenosis," Circ. Res. 86:829-33 (2000).
	AC	Larry L. SHEARS et al., "Efficient Inhibition of Intimal Hyperplasia by Adenovirus-Mediated Inducible Nitric Oxide Synthase Gene Transfer to Rats and Pigs *In Vivo*," J. Am. Coll. Surg., 187(3):295-306 (1998).
	AD	Russell ROSS, "The pathogenesis of atherosclerosis: a perspective for the 1990s," Nature, 362:801-9 (1993).
	AE	J. Evan SADLER, "Thrombomodulin Structure and Function," Tehomb Haemost., 78:392-5 (1997).
	AF	Charles T. ESMON, "Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface," Faseb J., 9:946-55 (1995).
	AG	Veikko SALOMAA et al., "Soluble thrombomodulin as a predicctor of incident coronary heart disease and symptomless carotid artery atherosclerosis in the Atherosclerosis Risk in Communities (ARIC) Study: a case-cohort study," Lancet, 353:1729-34 (1999).
	AH	R.M.J. PALMER et al., "Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor," Nature, 327:524-6 (1987).
	AI	P. KUBES et al., "Nitric oxide: An endogenous modulator of leukocyte adhesion," Proc. Natl. Acad. Sci. USA, 88:4651-5 (1991).
	AJ	P. Gabriel STEG M.D., et al., "Reduction of Restenosis After Angioplasty in an Atheromatous Rabbit Model by Suicide Gene Therapy," Circulation, 96:401-11 (1997).
	AK	Eric VAN BELLE et al., "Accelerated Endothelialization by Local Delivery of Recombinant Human Vascular Endothelial Growth Factor Reduces In-Stent Intimal Formation," Biochem. and Biophs. Res. Communications, 235"311-6 (1997).
	AL	A. Neil SALYAPONGSE, M.D., et al., "GENE THERAPY AND TISSUE ENGINEERING," Tissue Engineering, 26(4):663-76 (1999).

EXAMINER [signature] DATE CONSIDERED 2/3/06

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

Form PTO 1449 (Modified) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 3840-005-27	SERIAL NO. 10/725,013
	APPLICANT Lakshman R. SEHGAL et al.	
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)	FILING DATE December 2, 2003	GROUP ART UNIT ~~1623~~ 1635

JUN 2 5 2004 PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES	TRANSLATION NO
	AB					
	AC					
	AD					
	AE					
	AF					

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

PL	AG	T. KON et al., "Bone Morphogenetic Protein-2-Stimulates Differentiation of Cultured Spinal Ligament Cells from Patients with Ossification of the Posterior Longitudinal Ligament," Calcif. Tissue Int. (1997) 60:291-6
	AH	
	AI	
	AJ	
	AK	
	AL	
	AM	
	AN	

EXAMINER [signature] DATE CONSIDERED 2/3/06

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.